Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development

Bioorganic and Medicinal Chemistry Letters

Volumn 26, Issue 5, 2016, Pages 1475-1479

  Nair, Anilkumar G ^a   Zeng, Qingbei ^a   Selyutin, Oleg ^a   Rosenblum, Stuart B ^a   Jiang, Yueheng ^a   Yang, De Yi ^a   Keertikar, Kerry ^a   Zhou, Guowei ^a   Dwyer, Michael P ^a   Kim, Seong Heon ^a   Shankar, Bandarpalle ^a   Yu, Wensheng ^a   Tong, Ling ^a   Chen, Lei ^a   Mazzola, Robert ^a   Caldwell, John ^a   Tang, Haiqun ^a   Allard, Melissa L ^b   Buckle, Ronald N ^b   Gauuan, Polivina Jolicia F ^b   Holst, Christian L ^b   Martin, Gregory S ^b   Naicker, Kannan P ^b   Vellekoop, Samuel ^b   Agrawal, Sony ^a   Liu, Rong ^a   Kong, Rong ^a   Ingravallo, Paul ^a   Xia, Ellen ^a   Zhai, Ying ^a   Nomeir, Amin ^a   Kozlowski, Joseph A ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b ALBANY MOLECULAR RESEARCH INC   (United States)

Author keywords

HCV; NS5a; Pan genotype

Indexed keywords

ANTIVIRUS AGENT; MK 4882; NONSTRUCTURAL PROTEIN 5A INHIBITOR; PROLINE DERIVATIVE; UNCLASSIFIED DRUG; NS-5 PROTEIN, HEPATITIS C VIRUS; PROLINE; SILANE DERIVATIVE; VIRAL PROTEIN;

ALKYLATION; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; EC50; GENOTYPE; IC50; IN VITRO STUDY; NONHUMAN; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; HEPACIVIRUS; MICROBIAL SENSITIVITY TEST; SYNTHESIS; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; GENOTYPE; HEPACIVIRUS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PROLINE; SILANES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84957840250     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2016.01.050     Document Type: Article

References (22)

1. D. Lavanchy Clin. Microbiol. Infect. 17 2011 107
2. J.T. Liang, J.H. Hoofnagle, and C. Hepatitis Biomedical Research Reports 2000 Academic Press London, UK 185 203
3. D.R. Bobeck, R.F. Schinazi, and S.J. Coats Antivir. Ther. 15 2010 935
4. C. Sheridan Nat. Biotechnol. 29 2011 553
5. R.F. Schinazi, L. Bassit, and C. Gavegnano J. Viral Hepat. 17 2010 77
6. M.G. Katze, B. Kwieciszewski, D.R. Goodlett, C.M. Blakely, P. Neddermann, S.L. Tan, and R. Aebersold Virology 278 2000 501
7. J. Kim, D. Lee, and J. Choe Biochem. Biophys. Res. Commun. 257 1999 777
8. M. Gao, R.E. Nettles, M. Belema, L.B. Snyder, V.N. Nguyen, R.A. Fridell, M.H. Serrano-Wu, D.R. Langley, J.-H. Sun, D.R. O'Boyle, J.A. Lemm, C. Wang, J.O. Knipe, C. Chien, R.J. Colonno, D.M. Grasela, N.A. Meanwell, and L.G. Hamann Nature 465 2010 96
9. R.E. Nettles, M. Gao, M. Bifano, E. Chung, A. Persson, T.C. Marbury, R. Goldwater, M.P. DeMicco, M. Rodriguez-Torres, A. Vutikullird, E. Fuentes, E. Lawitz, J.C. Lopez-Talavera, and D.M. Grasela Hepatology 54 2011 1956
10. A. Lok Clin. Liver Dis. 17 2013 111
11. J.-M. Pawlotsky J. Hepatol. 59 2013 375
12. O. Belda, and P. Targett-Adams Virus Res. 170 2012 1
13. D.G. Cordek, J.T. Bechtel, A.T. Maynard, W.M. Kazmierski, and C.E. Cameron Drugs Future 36 2011 691
14. G.M. Keating Drugs 75 2015 675
15. E.D. Deeks Drugs 75 2015 1027
16. C.A. Coburn, P.T. Meinke, W. Chang, C.A. Fandozzi, D.J. Graham, B. Hu, Q. Huang, S. Kargman, J. Kozlowski, R. Liu, J.A. McCauley, A.A. Nomeir, R.M. Soll, J.P. Vacca, D. Wang, H. Wu, B. Zhong, D.B. Olsen, and S.W. Ludmerer ChemMedChem 8 2013 1930
17. W. Bains, and R. Tacke Curr. Opin. Drug Discov. Devel. 6 2003 526
18. A.K. Franz, and S.O. Wilson J. Med. Chem. 56 2013 388
19. N.A. Meanwell J. Med. Chem. 54 2011 2529
20. Refer to patent WO2013039876 and WO2011112429 for detailed procedures and schemes.
21. B. Vivet, F. Cavelier, and J. Martinez Eur. J. Org. Chem. 2000 807
22. Refer to patent WO2011112429 for detailed procedures and schemes.